Regulatory receptor-ligand systems that prevent excessive immune activation–exploited by tumors to evade destruction.
Immune checkpoints evolved to prevent autoimmune destruction of healthy tissue. After T cell activation, inhibitory receptors like PD-1 and CTLA-4 are upregulated, creating a 'cooling off' mechanism that terminates the immune response once pathogens are cleared.
Without these brakes, activated T cells would continue attacking indefinitely–causing autoimmune disease. Checkpoints are essential for maintaining the balance between effective immunity and self-tolerance.
Why They Exist: Checkpoints are natural "off switches" that prevent immune cells from attacking too aggressively. They normally activate after infections to prevent autoimmune damage.
The Balance: Without checkpoints, immune cells would attack healthy tissue. With too many checkpoints (or too much engagement), immune cells can't attack cancer.
Cancer cells exploit checkpoint pathways by expressing ligands that bind inhibitory receptors on tumor-infiltrating lymphocytes. When PD-L1 on a tumor cell binds PD-1 on a T cell, it delivers a 'stop' signal that exhausts the T cell and prevents tumor killing.
This represents a form of adaptive resistance–tumors that survive initial immune attack often upregulate checkpoint ligands to create an immunosuppressive microenvironment.
Cancer's Escape: Tumors exploit checkpoints by expressing checkpoint ligands (like PD-L1) to tell infiltrating immune cells to stand down.
The Result: Even when immune cells recognize cancer, checkpoint engagement prevents them from attacking.
Current clinical assays measure checkpoint expression–whether PD-L1 or other ligands are present. But expression alone cannot determine whether the checkpoint is functionally engaged.
FRETLoading...-based approaches like iFRETLoading... measure the actual receptor-ligand interaction, detecting engagement within 1–10 nm. This functional measurement predicts clinical outcomes where expression fails.
The Critical Distinction: Expressing a checkpoint ligand and actually using it to suppress immunity are different things.
The Solution: FRET measures actual molecular engagement at the 1-10nm scale where checkpoints interact. This provides functional information that expression tests cannot.
Platform Validation: QF-Pro measures immune checkpoint interactions at 1-10nm resolution. Validated pairs include:
• PD-1/PD-L1: Predicts survival (P=0.05[3]) vs expression (P=0.87[3])
• CTLA-4/CD80: First-ever[4] tissue quantification at immune synapse resolution
Click citation numbers to view full references in QF-Pro Applications & Clinical EvidenceLoading...
Validated platform: QF-Pro measures checkpoint interactions at 1-10nm resolution. Validated for PD-1/PD-L1 (predicts survival) and CTLA-4/CD80 (first-ever tissue quantification).
